DOI QR코드

DOI QR Code

The Blood Neutrophil-to-lymphocyte Ratio Predicts Survival in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib

  • Zheng, You-Bing (Department of Interventional Radiology, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences) ;
  • Zhao, Wei (Department of Interventional Radiology, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences) ;
  • Liu, Bing (Department of Interventional Radiology, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences) ;
  • Lu, Li-Gong (Department of Interventional Radiology, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences) ;
  • He, Xu (Department of Interventional Radiology, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences) ;
  • Huang, Jian-Wen (Department of Interventional Radiology, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences) ;
  • Li, Yong (Department of Interventional Radiology, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences) ;
  • Hu, Bao-Shan (Department of Interventional Radiology, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences)
  • Published : 2013.09.30

Abstract

Background and Aim: Increasing evidence correlates the presence of systemic inflammation with poor survival in patients with hepatocellular carcinoma (HCC). The aim of this study was to investigate the prognostic significance of the blood neutrophil-to-lymphocyte ratio (NLR) in patients with advanced HCC who received sorafenib monotherapy. Methods: A total of sixty-five patients with advanced HCC, not eligible for locoregional therapy, treated with sorafenib were enrolled. Potential prognostic factors such as age, gender, tumoral characteristics, performance status and NLR were analyzed. Results: Median OS and TTP for the entire cohort were 10.0 months (95%CI, 7.6-12.3 months) and 4.5 months (95% CI, 4.0-4.9 months). The mean NLR at baseline was 2.89. The median OS of patients with a high NLR (>4) was 6.5 months (95%CI, 5.2-7.7 months) compared with 12.5 months (95%CI, 9.9-15.0) for patients with a normal NLR (${\leq}4$) (P=0.01). Age ${\leq}65$, NLR>4, extrahepatic metastases and vascular invasion were all predictors of poorer overall survival. Multivariate analysis showed that NLR > 4, vascular invasion and extrahepatic metastases were independent predictors of poorer overall survival. The median TTP of patients with a high NLR was 2.5 months (95%CI, 1.4-3.6 months) compared with 4.5 months (95%CI, 3.9-5.1 months) for patients with a normal NLR (P=0.012). Conclusions: High baseline NLR was associated with worse OS and TTP for patients with advanced HCC treated with sorafenib.

Keywords

Hepatocellular carcinoma;sorafenib;neutrophil-lymphocyte ratio

References

  1. Abou-Alfa GK, Schwartz L, Ricci S, et al (2006). Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol, 24, 4293-300 https://doi.org/10.1200/JCO.2005.01.3441
  2. Bruix J, Sherman M (2011). Management of hepatocellular carcinoma: an update. Hepatology, 53, 1020-2 https://doi.org/10.1002/hep.24199
  3. Carlomagno F, Anaganti S, Guida T, et al (2006). BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst, 98, 326-34 https://doi.org/10.1093/jnci/djj069
  4. Chen TM, Lin CC, Huang PT, Wen CF (2012). Neutrophilto- lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation. J Gastroenterol Hepatol, 27, 553-61 https://doi.org/10.1111/j.1440-1746.2011.06910.x
  5. Cheng AL, Kang YK , Chen Z, et al (2009). Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol, 10, 25-34 https://doi.org/10.1016/S1470-2045(08)70285-7
  6. Chew V, Tow C, Teo M, et al (2010). Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol, 52, 370-9
  7. Cho JY, Paik YH, Lim HY, et al (2013). Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma. Liver Int, 33, 950-7 https://doi.org/10.1111/liv.12168
  8. Coussens LM, Werb Z (2002). Inflammation and cancer. Nature, 420, 860-7 https://doi.org/10.1038/nature01322
  9. Ding PR, An X, Zhang RX, et al (2010). Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis, 25, 1427-33 https://doi.org/10.1007/s00384-010-1052-0
  10. Forner A, Llovet JM, Bruix J (2012). Hepatocellular carcinoma. Lancet, 379, 1245-55 https://doi.org/10.1016/S0140-6736(11)61347-0
  11. Gomez D, Farid S, Malik HZ, et al (2008). Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg, 32, 1757-62 https://doi.org/10.1007/s00268-008-9552-6
  12. Halazun KJ, Hardy MA, Rana AA, et al (2009). Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg, 250, 141-51 https://doi.org/10.1097/SLA.0b013e3181a77e59
  13. Hanahan D, Weinberg RA (2011). Hallmarks of cancer: the next generation. Cell, 144, 646-74 https://doi.org/10.1016/j.cell.2011.02.013
  14. Hsu CH, Shen YC, Lin ZZ, et al (2010). Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol, 53, 126-31 https://doi.org/10.1016/j.jhep.2010.01.035
  15. Hung HY, Chen JS, Yeh CY, et al (2011). Effect of preoperative neutrophil-lymphocyte ratio on the surgical outcomes of stage II colon cancer patients who do not receive adjuvant chemotherapy. Int J Colorectal Dis, 26, 1059-65 https://doi.org/10.1007/s00384-011-1192-x
  16. Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH (2003). Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis, 6, 283-7 https://doi.org/10.1023/B:AGEN.0000029415.62384.ba
  17. Iavarone M, Cabibbo G, Piscaglia F, et al (2011). Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology, 54, 2055-63 https://doi.org/10.1002/hep.24644
  18. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ (2000). Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxidedependent mechanism. Cancer Res, 60, 184-90
  19. Kuang DM, Zhao Q, Wu Y, et al (2011). Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol, 54, 948-55 https://doi.org/10.1016/j.jhep.2010.08.041
  20. Limaye AR, Clark V, Soldevila-Pico C, et al (2012). Neutrophillymphocyte ratio predicts overall and recurrence-free survival after liver transplantation for hepatocellular carcinoma. Hepatol Res, 43, 757-64.
  21. Llovet JM, Ricci S, Mazzaferro V, et al (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 359, 378-90 https://doi.org/10.1056/NEJMoa0708857
  22. McDonald B, Spicer J, Giannais B, et al (2009). Systemic inflammation increases cancer cell adhesion to hepatic sinusoids by neutrophil mediated mechanisms. Int J Cancer, 125, 1298-305 https://doi.org/10.1002/ijc.24409
  23. McNally ME, Martinez A, Khabiri H, et al (2013). Inflammatory markers are associated with outcome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization. Ann Surg Oncol, 20, 923-8 https://doi.org/10.1245/s10434-012-2639-1
  24. Minguez B, Lachenmayer A (2011). Diagnostic and prognostic molecular markers in hepatocellular carcinoma. Dis Markers, 31, 181-90 https://doi.org/10.1155/2011/310675
  25. Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T (1997). Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma. J Clin Oncol, 15, 826-32 https://doi.org/10.1200/JCO.1997.15.2.826
  26. Motomura T, Shirabe K, Mano Y, et al (2013). Neutrophillymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol, 58, 58-64 https://doi.org/10.1016/j.jhep.2012.08.017
  27. Ohtani H (2007). Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun, 7, 4
  28. Prete SD, Montella L, Caraglia M, et al (2010). Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So LAR study. Cancer Chemother Pharmacol, 66, 837-44 https://doi.org/10.1007/s00280-009-1226-z
  29. Therasse P, Arbuck SG, Eisenhauer EA, et al (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 92, 205-16 https://doi.org/10.1093/jnci/92.3.205
  30. Vincenzi B, Santini D, Russo A, et al (2010). Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist, 15, 85-92 https://doi.org/10.1634/theoncologist.2009-0143
  31. Wilhelm S, Chien DS (2002). BAY 43-9006: preclinical data. Curr Pharm Des, 8, 2255-7 https://doi.org/10.2174/1381612023393026

Cited by

  1. Is the Combination of Neutrophil to Lymphocyte and Platelet to Lymphocyte Ratios a Useful Predictor of Treatment Response and Prognosis in Patients with Non-Small Cell Lung Cancer? vol.15, pp.10, 2014, https://doi.org/10.7314/APJCP.2014.15.10.4373
  2. Treatment of Metastatic Colorectal Cancer With or Without Bevacizumab: Can the Neutrophil/Lymphocyte Ratio Predict the Efficiency of Bevacizumab? vol.15, pp.12, 2014, https://doi.org/10.7314/APJCP.2014.15.12.4781
  3. Prognostic Significance of the Peripheral Blood Absolute Monocyte Count in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma Receiving Systemic Chemotherapy vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6387
  4. Albumin-globulin Ratio for Prediction of Long-term Mortality in Lung Adenocarcinoma Patients vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6449
  5. Predictive Role of the Neutrophil-to-Lymphocyte Ratio in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib vol.15, pp.2, 2014, https://doi.org/10.7314/APJCP.2014.15.2.1063
  6. Could the Neutrophil to Lymphocyte Ratio be a Poor Prognostic Factor for Non Small Cell Lung Cancers? vol.15, pp.5, 2014, https://doi.org/10.7314/APJCP.2014.15.5.2089
  7. Prognostic Value of Hematologic Parameters in Patients with Metastatic Renal Cell Carcinoma Using Tyrosine Kinase Inhibitors vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3801
  8. Inflammation-based scores do not predict post-transplant recurrence of hepatocellular carcinoma in patients within milan criteria vol.20, pp.11, 2014, https://doi.org/10.1002/lt.23969
  9. Neutrophil–lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib vol.31, pp.6, 2014, https://doi.org/10.1007/s12032-014-0969-5
  10. Prognostic Significance of the Neutrophil-to-Lymphocyte Ratio in Primary Liver Cancer: A Meta-Analysis vol.9, pp.5, 2014, https://doi.org/10.1371/journal.pone.0096072
  11. Platelet to lymphocyte ratio as a new prognostic for patients with metastatic renal cell cancer vol.11, pp.4, 2015, https://doi.org/10.1111/ajco.12358
  12. An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib pp.1699-3055, 2017, https://doi.org/10.1007/s12094-017-1720-4
  13. Blood Neutrophil-to-Lymphocyte Ratio Predicts Tumor Recurrence in Patients with Hepatocellular Carcinoma within Milan Criteria after Hepatectomy vol.57, pp.5, 2016, https://doi.org/10.3349/ymj.2016.57.5.1115
  14. Systemic immune-inflammation index in germ-cell tumours vol.118, pp.6, 2018, https://doi.org/10.1038/bjc.2017.460
  15. hepatic arterial infusion chemotherapy vol.10, pp.9, 2018, https://doi.org/10.4254/wjh.v10.i9.571
  16. High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors pp.0960-8931, 2018, https://doi.org/10.1097/CMR.0000000000000461
  17. Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis vol.67, pp.5, 2018, https://doi.org/10.1007/s00262-018-2126-z